The well-established antimuscarinic drug class dominates the overactive bladder (OAB) therapy market, and the continued generic erosion of these agents will be the most significant constraint on the market’s future growth. However, for patients in whom these drugs are not effective, the options are limited. The two most recent market entrants, Astellas’s Myrbetriq and Allergan’s Botox (both of which offer alternative MOAs), have enjoyed strong growth in this market driven by a need for therapies effective in patients who are refractory to the antimuscarinics, by direct-to-consumer promotion, and by life-cycle management strategies used by their developers.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Botox, Myrbetriq, oxybutynin, Vesicare
Key analysis provided: